These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 9718944)

  • 21. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
    Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
    Koopmans SM; van Marion AM; Schouten HC
    Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [MYELOPROLIFERATIVE SYNDROMES].
    PIRESWDA F
    Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
    Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myeloproliferative disorders (CMPD).
    Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
    Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.